EU Health Research Funding - Crui: Conferenza dei Rettori

download report

Transcript EU Health Research Funding - Crui: Conferenza dei Rettori

EU support for Health Research:
from FP6 to FP7
Beatrice Lucaroni
Unit F4
DG Research - European Commission
Ferrara – 25 Ottobre 2006
EU Health Research
Perspectives for the 7th Framework Programme
The details of the FP7 priorities and modalities are still in negotiation and subject
to change. In particular the EC’s proposal for the Joint Technology Initiative for
Innovative Medicines will be subjected to the approval of the European Council.
Role of EC in research
European Commission programmes bring down barriers
• between countries:
– multinational consortia in Europe (EU-25 + associated countries)
– researchers from almost any country in the world can participate;
and promotes coordination of national funding programmes (ERA)
• between different types of organizations:
universities, research centres, SMEs, large companies, etc.
• between disciplines: focus on translational research
and encourages mobility: Marie Curie fellowships for researchers
and for host institutes, including ingoing & outgoing grants.
EC Research
Framework Programme 6
• €2.4 billion in research grants for 604 projects in 4 years
• Average success rate for projects: 25.4%
• Total number of participants: 7,426
Project type
av. EU contribution
Integrated Projects
€ 10.0m
€ 9.3m
€ 2.2m
Coordination Actions
€ 1.1m
Specific Support Actions
€ 0.4m
Networks of Excellence
Special call
for SME projects
in Health research (2006)
• 355 proposals received: 86 projects funded
• € 200 million granted: 43% going to SMEs
• Average budget requested per SME: € 342,000
• ~270 SMEs involved (41% of participants)
• 40/86 projects (46%) coordinated by SMEs
• SMEs taking leading role in projects
• projects aligned with SME’s strategy
• SME gaining experience in EC funding schemes
FP7: main elements
 Budget to be increased: €50.5 billion over 7 years
+ 40%
 European Research Council ( Ideas )
 Collaborative research ( Cooperation )
continuity in themes & instruments.
funding levels to be raised in some cases, eg SMEs: 50%  75%
Joint Technology Initiatives
 Infrastructures, SMEs, regions & potential ( Research Capacities )
 Human potential and science careers ( People )
The European Commission currently manages about 5%
of total public spending in R&D in the European Union.
The EU currently invests about 1.9% of GDP in research
FP7 budget
(EUR billion, 2004 constant prices)
Collaborative research in FP7
Thematic Priorities
Food, agriculture and biotechnology
Information and communication technologies
Nanosciences, nanotechnologies, materials
and new production technologies
Environment (including climate change)
Transport (including aeronautics)
Socio-economic sciences and the humanities
Security and space
Euratom: fusion energy research, nuclear fission
and radiation protection
Collaborative research
for Health in FP7
Main policy drivers:
 Improving health of European citizens
 Increasing competitiveness of European
health-related industries and businesses
 Addressing global health issues,
including emerging epidemics
Collaborative research
for Health in FP7
 €6 billion over 7 years (2007-2013)
Activities in 3 main areas
• Biotechnology, generic tools and technologies
for human health
• Translating research for human health
• Optimising the delivery of healthcare
Collaborative research
for Health in FP7
1: Biotechnology, generic tools and technologies
 High-throughput research
enhancing data generation, standardisation, acquisition & analysis
 Detection, diagnosis and monitoring
with emphasis on non-invasive or minimally invasive approaches
 Innovative therapeutic approaches and interventions
gene and cell therapy, regenerative medicine, transplantation,
immunotherapy and vaccines, implants & prosthetics
 Predicting suitability, safety and efficacy of therapies
develop and validate parameters, tools, methods and standards
(mainly through IMI) and alternatives to animal testing
Collaborative research
for Health in FP7
2: Translating research for human health
 Integrating biological data and processes:
large-scale data gathering, systems biology
 Research on the brain and related diseases,
human development and ageing
 Translational research in major infectious diseases:
to confront major threats to public health
antimicrobial drug resistance, HIV/AIDS, malaria and TB,
emerging epidemics, neglected infectious diseases
 Translational research in other major diseases:
cancer, cardiovascular disease, diabetes and obesity,
rare diseases, and other chronic diseases
Collaborative research
for Health in FP7
3: Optimising the delivery of health care
 Enhanced health promotion and disease prevention
(providing evidence of best public health measures – life styles,
interventions, special focus on mental health, etc.)
 Translating clinical research into clinical practice
(patient safety, better use of medicines, benchmarking,
pharmacovigilance, etc.)
 Quality, solidarity and sustainability of health systems
(organisational and financial aspects, health systems, etc.)
Collaborative research
for Health in FP7
Two other issues will be addressed across all activities:
 Child health
 The health of the ageing population
For more information see Specific programme:
Collaborative research
for Health in FP7
Special encouragement and measures for:
 SMEs
 Participation of SMEs and larger companies in all areas
 Special topics for SMEs
 International Cooperation
 Participation possible in all areas
 Special International Cooperation Actions (SICA)
Translational sciences
Dialog among basic and clinical scientists
Forward Translation:
-Use bioinformatics, functional
genomics into clinical practice
- Develop biomarkers & molecular
imaging techniques at early stage
of target validation
Phase I – II – III
In vitro studies
Animal models
Reverse Translation:
- Validating the biochemistry in
target & biomarker discovery
Target validation
Basic research
- Bring measurements from the
clinic into earlier stages of basic
Collaborative research
for Health in FP7
Continuity in collaborative Health research to:
 develop new tools and technologies
 promote translational research
 enhanced efforts to optimise delivery of health care
[ using usual FP funding and coordination mechanisms ]
A novel approach to improve drug development:
 The Innovative Medicines Initiative
[ using the proposed Joint Technology Initiative in FP7 ]
Research funding
schemes in FP7
Funding instruments proposed:
 Collaborative projects to develop new knowledge, new technology,
products, demonstration activities
 Small or medium-sized focused research actions
 Large-scale integrating projects
 Projects targeted at special groups (eg SMEs or International)
 Networks of Excellence
 Coordination and support actions
 Support for investigator driven research by individual teams (ERC)
 Support for training and career development of researchers
 Research for the benefit of specific groups (in particular SMEs)
Basic principles
of evaluation and funding
• Annual calls for proposals, with topics set by the EC
(following consultation and approval by Member States).
• Proposals evaluated by panels of independent experts
(being an expert for the EC is a valuable experience)
• Criteria and thresholds
• Proposals short-listed for funding (with recommendations)
• Consortia receive EC funding for R&D tasks (shared cost)
and for project management
• 12- of 18-month reports and reviews
Collaborative research
for Health in FP7
Next steps:
• Approval by Council and European Parliament
• Preparation of work programmes for years 1 & 2.
 Currently consulting Member and Associated States (PC)
• First calls for proposals: Dec. 2006 (tbc)
 first deadline end-March ’07 (tbc)
 second deadline end-June ’07 (tbc)
[ not all areas will be open at in each call ]
Information on FP7
• EU research:
• Seventh Framework Programme:
• Information on research programmes and projects:
• RTD info magazine:
• Innovative Medicines Initiative
• Information requests:
[email protected]
[email protected]